USD
$0.00
(0.00%
)At Close (As of Oct 16, 2025)
$777.29M
Market Cap
55.5
P/E Ratio
0.12
EPS
$7.50
52 Week High
$4.71
52 Week Low
FINANCIAL SERVICES
Sector
Field | Value (USD) |
---|---|
Gross Profit | $41M |
Total Revenue | $41M |
Cost Of Revenue | - |
Costof Goods And Services Sold | - |
Operating Income | $36M |
Selling General And Administrative | $4.4M |
Research And Development | - |
Operating Expenses | $5M |
Investment Income Net | - |
Net Interest Income | -$15K |
Interest Income | $0 |
Interest Expense | $15K |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | - |
Income Before Tax | $36M |
Income Tax Expense | - |
Interest And Debt Expense | - |
Net Income From Continuing Operations | $36M |
Comprehensive Income Net Of Tax | - |
Ebit | - |
Ebitda | - |
Net Income | $36M |
Field | Value (USD) |
---|---|
Total Assets | $1.8B |
Total Current Assets | - |
Cash And Cash Equivalents At Carrying Value | $0 |
Cash And Short Term Investments | $0 |
Inventory | - |
Current Net Receivables | $67K |
Total Non Current Assets | - |
Property Plant Equipment | - |
Accumulated Depreciation Amortization Ppe | - |
Intangible Assets | - |
Intangible Assets Excluding Goodwill | - |
Goodwill | - |
Investments | - |
Long Term Investments | $1.8B |
Short Term Investments | - |
Other Current Assets | -$67K |
Other Non Current Assets | - |
Total Liabilities | $24M |
Total Current Liabilities | - |
Current Accounts Payable | $0 |
Deferred Revenue | - |
Current Debt | - |
Short Term Debt | - |
Total Non Current Liabilities | - |
Capital Lease Obligations | - |
Long Term Debt | - |
Current Long Term Debt | - |
Long Term Debt Noncurrent | - |
Short Long Term Debt Total | - |
Other Current Liabilities | $182 |
Other Non Current Liabilities | - |
Total Shareholder Equity | $1.8B |
Treasury Stock | - |
Retained Earnings | -$1.9B |
Common Stock | $3.7B |
Common Stock Shares Outstanding | $216M |
Field | Value (USD) |
---|---|
Operating Cashflow | $277M |
Payments For Operating Activities | - |
Proceeds From Operating Activities | - |
Change In Operating Liabilities | - |
Change In Operating Assets | - |
Depreciation Depletion And Amortization | - |
Capital Expenditures | $0 |
Change In Receivables | - |
Change In Inventory | - |
Profit Loss | - |
Cashflow From Investment | - |
Cashflow From Financing | -$277M |
Proceeds From Repayments Of Short Term Debt | - |
Payments For Repurchase Of Common Stock | - |
Payments For Repurchase Of Equity | - |
Payments For Repurchase Of Preferred Stock | - |
Dividend Payout | $185M |
Dividend Payout Common Stock | $185M |
Dividend Payout Preferred Stock | - |
Proceeds From Issuance Of Common Stock | - |
Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
Proceeds From Issuance Of Preferred Stock | - |
Proceeds From Repurchase Of Equity | -$92M |
Proceeds From Sale Of Treasury Stock | - |
Change In Cash And Cash Equivalents | - |
Change In Exchange Rate | - |
Net Income | $36M |
Field | Value (USD) |
---|---|
Gross Profit | $41M |
Total Revenue | $41M |
Cost Of Revenue | - |
Costof Goods And Services Sold | - |
Operating Income | $36M |
Selling General And Administrative | $4.4M |
Research And Development | - |
Operating Expenses | $5M |
Investment Income Net | - |
Net Interest Income | -$15K |
Interest Income | $0 |
Interest Expense | $15K |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | - |
Income Before Tax | $36M |
Income Tax Expense | - |
Interest And Debt Expense | - |
Net Income From Continuing Operations | $36M |
Comprehensive Income Net Of Tax | - |
Ebit | - |
Ebitda | - |
Net Income | $36M |
Field | Value |
---|---|
Ex Dividend Date | 2025-10-15 |
Declaration Date | 2025-09-10 |
Record Date | 2025-10-15 |
Payment Date | 2025-10-31 |
Amount | 0.0525 |
Sector: FINANCIAL SERVICES
Industry: ASSET MANAGEMENT
Brooklyn ImmunoTherapeutics, Inc. (BTX) is a clinical-stage biopharmaceutical company headquartered in Brooklyn, New York, specializing in the development of cutting-edge cellular and genetic therapies for cancer treatment. Leveraging its proprietary technology platforms, the company is committed to addressing critical unmet medical needs in oncology. With a strong focus on research and development, Brooklyn ImmunoTherapeutics aims to improve patient outcomes and enhance the quality of life for cancer patients worldwide, positioning itself as a prominent player in the rapidly evolving field of cancer therapeutics.